期刊文献+

厄贝沙坦胃滞留夹芯渗透泵片的制备及体外释放度考察 被引量:3

Preparation and Dissolution Test in Vitro of Intragastric Floating Sandwiched Osmotic Pump Tablets of Irbesartan
原文传递
导出
摘要 目的对厄贝沙坦胃滞留夹芯渗透泵片(SOPT)的制备方法进行研究,并考察其体外释放度。方法分别以膨胀速度、水渗透速率、低剪切黏度、屈服应力及释放度为评价指标,确定处方中膨胀剂材料、致孔剂、助悬剂、促渗剂的用量。结果最佳处方:膨胀剂为PEO(Mw 5 000 000)与HPMC混合物(4∶1),用量70 mg;促渗剂氯化钠用量为25 mg;包衣液致孔剂PEG400用量8%;助悬剂PEO(Mw 200 000),用量为厄贝沙坦的1/4。释药行为符合零级方程,具有明显的控释特征。结论 SOPT具有良好的体外控释效果,可进一步进行体内释药行为考察。 OBJECTIVE To study prescription and technique of intragastric floating sandwiched osmotic pump tablets (SOPT) of irbesartan and inspect release property in vitro. METHODS The swelling rate, permeation rate of water, shear viscosity of slow-speed revolution, yield stress and release property was inspected to determine the dosage of the swelling agent, porous agent, suspending agent and osmotic agent. RESULTS The optimization of prescription and technique were definited: swelling agent was a mixture of PEO(Mw 5 000 000) and HPMC as a ratio of 4 : 1 (the dosage was 70 mg); osmotic agent sodium chloride was 25 mg; porous agent PEG 400 was 8%; the ratio of suspending agent PEO(Mw 200 000) to irbesartan was 1 : 4. The release behavior of SOPT coincidented with zero-level equation well and the character of controlled-release was transparent. CONCLUSION SOPT has good controlled-release in vitro and the release behavior in vivo need to be investigated.
出处 《中国现代应用药学》 CAS CSCD 2013年第2期154-157,共4页 Chinese Journal of Modern Applied Pharmacy
关键词 厄贝沙坦 夹芯渗透泵片 胃滞留 体外释放 irbesartan sandwiched osmotic pump tablets intragastric floating release in vitro
  • 相关文献

参考文献3

二级参考文献10

共引文献9

同被引文献44

  • 1孙小彤,谭一宁,李巧云,邹梅娟,程刚.酒石酸美托洛尔延迟缓释片的制备[J].中国药剂学杂志(网络版),2014,12(6):185-192. 被引量:2
  • 2欧阳斌,刘科秋.渗透泵制剂的研究进展[J].中国药房,2007,18(28):2227-2228. 被引量:5
  • 3Malaterre V,Ogorka J,Loggia N,et al.Oral osmotically driven systems:30 years of development and clinical use[J].Eur J Pharm Biopharm,2009,73(3):311-323.
  • 4Verma RK,Krishna DM,Garg S.Formulation aspects in the development of osmotically controlled oral drug delivery systems[J].J Control Release,2002,79(1/3):7-27.
  • 5Prabakaran D,Singh P,Kanaujia P,et al.Modified pushpull osmotic system for simultaneous delivery of theophylline and salbutamol:development and in vitro characterization[J].Int J Pharm,2004,284(1/2):95-108.
  • 6Waterman KC,Mac Donald BC,Roy MC.Extrudable core system:development of a single-layer osmotic controlledrelease tablet[J].J Control Release,2009,134(3):201-206.
  • 7Philip AK,Pathak K.Osmotic flow through asymmetric mem Brane:a means for controlled delivery of drugs with varying solubility[J].AAPS Pharm Sci Tech,2006,7(3):56.
  • 8Am Ende MT,Miller LA.Mechanistic investigation of drug release from asymmetric membrane tablets:effect of media gradients(osmotic pressure and concentration),and potential coating failures on in vitro release[J].Pharm Res,2007,24(2):288-297.
  • 9Patel H,Patel U,Kadikar H,et al.A review on osmotic drug delivery system[J].IRJP,2012,3(4):88-94.
  • 10Khan ZA,Tripathi R,Mishra B.Floating elementary osmotic pump tablet(FEOPT)for controlled delivery of diethylcarbamazine citrate:a water-soluble drug[J].AAPS Pharm Sci Tech,2011,12(4):1312-1323.

引证文献3

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部